A Phase I/II Dose Escalation Clinical Trial to Assess Safety and Efficacy of VG101 to Treat the Symptoms of Vulvar and Vaginal Atrophy in Post-Menopausal Women.

Trial Profile

A Phase I/II Dose Escalation Clinical Trial to Assess Safety and Efficacy of VG101 to Treat the Symptoms of Vulvar and Vaginal Atrophy in Post-Menopausal Women.

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs VG 101 (Primary)
  • Indications Genitourinary atrophy
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2011 Planned end date changed from 1 Aug 2011 to 1 Aug 2013 as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Planned end date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 14 Apr 2008 The trial is expected to commence later in 2008, according to a Bionovo media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top